The FDA-Approved Secretagogue the Community Underuses

Most of the growth hormone peptide catalog runs on folklore, and then there is tesamorelin, a compound that cleared FDA review on a registration program of hundreds of patients, yet still reads like a niche footnote beside the GLP-1s and CJC stacks. This article walks the tesamorelin record from the Egrifta approval to the 2 mg daily protocol, the visceral-fat numbers, the rebound on discontinuation, and why the community ranks it above sermorelin and CJC-1295. The material is community-sourced and assembled for research purposes, it is not medical advice, and nothing here is a treatment claim.

I · The approved drug the community treats like a rumor

The oddest fact about the secretagogue category is that the one drug with a finished regulatory journey is the one the forums treat as an afterthought. Tesamorelin was developed by Theratechnologies and marketed as Egrifta, an FDA-approved treatment for the excess abdominal fat of treated HIV patients, and when a forum poster waved it off as just another research compound, the reply became a community set piece: “This is literally broscience nonsense. Tesamorelin is an FDA-approved drug that was developed by a company called Theratechnologies. It is their flagship drug to this day, marketed as Egrifta.” [anecdotal] ¹ The correction matters because it names the difference between tesa and almost everything else sold in the space: the approval process ran on actual clinical data, and the gray market inherited a drug with a paper trail instead of a rumor trail. ²

The underuse has practical roots, because Egrifta was approved for a narrow HIV-associated indication and never marketed to the biohacking crowd, so it sat on pharmacy shelves while louder-reputation compounds took over the forums. The experienced community voice whose trial reading anchors much of this discourse keeps a blunt pecking order, tesamorelin clearly above sermorelin and CJC-1295 no DAC, with his one-line summary of the gray-market menu being “Tesa is the only one of the three that’s even close to worth the money.” [anecdotal] ² The approval rested on a substantial program, since two phase 3 trials randomized 806 HIV patients 2:1 to 2 mg daily or placebo, with computed tomography measuring visceral fat as the primary endpoint, ³ and a separate 12-month trial with a 6-month open-label phase extended the daily-dosing record to 18 months, the window the community cites when defending continuous use. ⁴

II · What the registration trials measured

The primary endpoint was the proportional change in visceral adipose tissue measured by computed tomography at week 26, and the pooled result was striking for its selectivity. Visceral fat fell by an average of 24 cm² in the drug group while the placebo group’s average moved up by 2 cm², a treatment effect of about 15.4%, and the subcutaneous fat layer stayed essentially where it was, a first hint that the drug does something anatomical that a calorie deficit alone does not reproduce. ³ By week 52, patients who stayed on 2 mg daily held a reduction of about 35 cm² from baseline, roughly 17.5%, the anchor for the community’s reading of the program. ³ The 12-month figure that circulates in the forums settles at the same value, with visceral fat down from 209 cm² at baseline to 193 cm², a drop of about 16 cm² or 7.6%, the same story told in raw numbers. ⁶

The selectivity has a mechanism story, because tesamorelin is a GHRH analog, a copy of the hypothalamic signal that triggers pituitary growth hormone pulses, and the community’s model is that the GH does the work: “They both just cause pulsatile GH release, that’s it. It’s the GH that is doing the work.” [anecdotal] ⁷ Growth hormone stimulates lipolysis and shapes where fat gets stored, which is why the community’s explanation for the effect resists the lifestyle translation: “Comparatively the reduction in visceral fat achieved by tesamorelin is driven by pharmacologically-mediated alterations in how and where the body stores lipids.” [anecdotal] ⁷ The follow-up line makes the same point with less ceremony: “It’s not as if eating kale and oats is magically going to activate STAT5 pathway for you.” [anecdotal] ⁷

The weight-neutral framing belongs right here, because the trials and the label describe the drug as weight-neutral, the maker’s language relaying “no significant effects on… weight” and the community repeating the point as a warning: “Tesa isn’t known for causing weight loss.” [anecdotal] ⁸ The distinction between moving the scale and moving the distribution is the hinge of the whole article, since anyone expecting GLP-1-style scale numbers will misread the drug within the first month.

III · The rebound that comes with the territory

The same trial record that established the effect also established its lifespan, because the reduction is pharmacologically driven and maintained. The community’s summary of the on-off arc is a single sentence: “You get the big visceral fat reduction you’d expect while taking rhGH, and then it all comes back after you stop.” [anecdotal] ⁹ A second voice frames the mechanism in storage terms: “Apparently when you stop pharmacologically altering where your body stores fat, your body reverts to storing fat how it used to.” [anecdotal] ⁹ The underlying issue is that the drug redirects where fat is stored while it runs, and the blunt corollary: “The problem is that they don’t really do anything to fix the underlying issue of why your body wants to store fat there, so when you stop taking them the fat generally goes back to where it was before.” [anecdotal] ⁹ The published record agrees, since the trial literature describes a prompt return of truncal obesity once treatment stops. ⁹

The rebound is also why the community corrects the weight-loss misreading, because someone who reports losing weight on tesa gets the same reply every time: the deficit did the work, since “Tesa isn’t known for causing weight loss.” [anecdotal] ⁸ This matters for anyone arriving from the GLP-1 world, because the GLP-1s move the scale while tesa moves the distribution, and the two outcomes demand different expectations and protocols, which is why the monitoring loop in the final sections is the practical heart of this article.

IV · Why the pecking order puts tesa on top

The pecking order appears wherever the community compares the three GHRH-class drugs, tesamorelin first and sermorelin and CJC-1295 no DAC below, and the reasoning splits into a dose problem and a data problem. The sermorelin comparison starts with dose, because adult trials had to push sermorelin to 2 mg per day, given as 1 mg twice daily, before IGF-1 moved distinguishably from placebo, while the protocol sheets circulate at a fraction of that dose. ¹⁰ The community’s shorthand for the gap is a single comparison:

You’ll see serm trials run 500mcg 2x/day to boost IGF-1 by 20%. Meanwhile 2mg of tesa will boost IGF-1 over 100%.

Community educator, Reddit peptide discourse, 2025-2026

The CJC comparison is a data-void story, because CJC-1295 without DAC, sold under names like mod-GRF, is a sermorelin variant with four amino acid substitutions, and the community’s fact-check on its evidence base is withering: “There are zero clinical trials for CJC-1295 no DAC. There aren’t even any published mouse studies.” [anecdotal] ¹¹ With-DAC CJC is a different drug, one that raises basal growth hormone on a different schedule with a half-life measured in days, so the no-DAC version gets treated as the community’s default CJC while being the least studied of the three. ¹¹ On results, the comparison runs against CJC as well, since “Tesamorelin is a lot more effective than CJC, both for cutting visceral fat and for anabolics.” [anecdotal] ¹⁰ Stacking the two makes little sense, because both hit the same GHRH receptor, which is why the community’s verdict is short: “CJC and tesa are duplicative of each other.” [anecdotal] ¹² The advice that follows is shorter still: “Pick a fighter bro.” [anecdotal] ¹²

Ipamorelin sits outside this ranking, because it works on a different receptor, the ghrelin receptor, a companion molecule for the GHRH drugs, and the community describes the combination as “Kind of a 2 + 2 = 6 situation” [anecdotal] ¹³ since a microdose of the ghrelin agonist potentiates the GHRH signal. The caution is appetite, because ghrelin agonism is a feeding signal first, which is why ipamorelin’s reputation runs to hunger at effective doses. The pecking order applies to the GHRH class itself, and tesa wins that class on dose, on data, and on the visceral-fat record.

V · The 2 mg daily protocol and the myths around it

The dosing record is unambiguous, because the registration program ran 2 mg daily by design: “In the clinical trials for tesa they had patients take 2mg every single day (no recommendation to take it fasted) for a year.” [anecdotal] ¹⁴ Steady-state IGF-1 takes about 3 to 4 weeks to arrive, which makes a week-two judgment premature and puts the real decision point at the four-to-six-week follow-up draw. ¹⁵

The fasting requirement is the first myth the record removes, because the manufacturer never asked for it: “Theratechnologies, the company that designed and makes tesamorelin as their flagship product, does not recommend taking it fasted. Nor did the successful clinical trials that led to the drug’s approval have participants taking it fasted.” [anecdotal] ¹⁶ The community’s verdict on the folklore is categorical: “The whole ‘must be taken fasted’ thing is an invention of the peptide community and has dubious clinical merit.” [anecdotal] ¹⁶ There is real physiology underneath the argument, since fasting can suppress hepatic IGF-1 production, and in people with obesity or a history of it the GHRH response can be stronger after a meal, with the community’s n=1 testing reporting roughly double the IGF-1 response postprandial, [anecdotal] [secondhand] ¹⁷ so the honest summary is that the fasted rule was never in the label and the evidence tilts the other way for many users.

The cycling requirement is the second myth, because the same continuous-dosing program that ran a year straight supports the community’s position: “There’s no reason to cycle the secretagogues. You can just run them continuously for as long as you want the effect of the drug, they keep working.” [anecdotal] ¹⁸ The pharmacodynamic record points the same direction, since a population pharmacokinetic analysis of tesamorelin found the growth hormone response improving over the first two weeks of daily dosing, a receptor training effect that the community reads as the opposite of burnout, ¹⁸ and the folklore that 1 mg saturates while 2 mg is waste runs against trials showing stronger effects past that point. ¹⁸

Month one brings its own surprise, because growth hormone retains water: “People normally gain 5-10 pounds of water weight in the month after starting tesa because growth hormone causes a lot of water retention.” [anecdotal] ⁸ The community’s advice is to log the scale and ignore the number, since the gain is water and the weight-neutral profile means the scale settles.

VI · The labwork the protocol runs on

Growth hormone is pulsatile, which makes a single GH draw close to meaningless, and IGF-1 is the stable proxy the community runs on, since it reflects the integrated output of the axis over the preceding weeks. The monitoring protocol, in the community’s own words:

Get baseline IGF-1. Follow up after a month of therapy and see what effect you’re getting. Continue periodic checks after that. Adjust your approach as needed.

Community educator, Reddit peptide discourse, 2025-2026

The loop works in both directions, because the same follow-up draw that catches an underdosed protocol also catches the over-responder. On the high side, the reports are pointed: “I’ve seen people push themselves deep into acromegaly territory using secretagogues. One person I spoke with had an IGF-1 well over 500.” [anecdotal] ¹⁹ The corollary is that running these drugs without bloodwork gets called “horrible and reckless advice” [anecdotal] ¹⁹ by the same voice, since an IGF-1 draw costs about $14 to $19 through community lab subscriptions and answers what no protocol sheet can. ¹⁹

The hedged equivalences belong in this section, because they are community synthesis and should be read as such. The common claim that 2 mg of tesa approaches low-dose growth hormone therapy, “2mg of tesa will give you similar effects to low-dose growth hormone.”, [anecdotal] ²⁰ is a community-synthesized equivalence, and the cost claim that “HGH is both more effective and cheaper” [anecdotal] ²⁰ comes with its own math, since a 10-vial kit of 10 mg at 2 mg per day covers 50 days and the totals add up against gray HGH pricing. ²⁰ Both claims stay hedged in the source discourse, and the choice between a secretagogue and exogenous GH depends on the goal, because secretagogues push the axis within the physiological range while exogenous GH goes supraphysiological. ²⁰

VII · What the trials leave open

The registration program measured fat by computed tomography and tracked lipids and glucose, reporting no clinically meaningful changes in glucose parameters across 26 and 52 weeks, which answers one GH-class worry in one direction. ³ The program did not follow hard outcomes, so whether a maintained 35 cm² visceral-fat reduction translates into fewer cardiovascular events remains an open question, one the community states plainly. ³ The trial windows themselves are the second limit, because a year of data, or 18 months in the open-label program, is a short runway for a drug designed for continuous use, with the evidence thinning past those windows. ⁴

The other open questions sit closer to practice. The fed-versus-fasted question was never set up as a trial arm, so the postprandial paradox rests on GHRH studies in other populations plus community n=1 testing, promising but preliminary. ¹⁷ The lifelong-use math belongs on the table before the first vial, because the rebound makes tesa a continuous therapy and the cost compounds, with the community’s honest note being that the visceral-fat effect requires continued dosing for continued benefit. ⁹ And the drug’s market history raises a question the trial record cannot answer, since Egrifta stayed inside its HIV indication for commercial reasons that have nothing to do with pharmacology. ²

Tesamorelin earns the attention because the community’s enthusiasm and the trial record point the same direction, which is rare in this category: 2 mg daily, IGF-1 labs, continuous, VAT-specific, weight-neutral, and reversible on stop. The underuse is the anomaly, and the evidence base is the ordinary part. For anyone treating this as research material, the protocol is the documented one, the monitoring is cheap, and the honest limits are the open questions above.

This article is community-sourced protocol analysis assembled for research purposes; it is not medical advice, and it is not a treatment claim for any condition. Tesamorelin is an FDA-approved drug in a specific indication, the other compounds discussed here are research substances, and anyone handling these peptides should do so under appropriate oversight with tested product and honest records, and a monitoring plan that includes labwork.